161785-96-2Relevant academic research and scientific papers
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
Meden, An?e,Knez, Damijan,Juki?, Marko,Brazzolotto, Xavier,Gr?i?, Marija,Pi?lar, Anja,Zahirovi?, Abida,Kos, Janko,Nachon, Florian,Svete, Jurij,Gobec, Stanislav,Gro?elj, Uro?
, p. 3765 - 3768 (2019/04/01)
We have identified tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors. They are defined according to their chemical modularity, novel binding mode revealed by five solved crystal structures with human BChE, low cytotoxicity, and predicted permeability of the blood-brain barrier. Altogether, these factors indicate their potential as unique lead compounds for symptomatic therapy against Alzheimer's disease.
Addition of carboxyalkyl radicals to alkenes through a catalytic process, using a Mn(II)/Co(II)/O2 redox system
Hirase, Koji,Sakaguchi, Satoshi,Ishii, Yasutaka
, p. 5974 - 5976 (2007/10/03)
A novel strategy for production of mono- and dicarboxylic acids by the addition of carboxyalkyl radicals to alkenes and dienes, respectively, was successfully developed through a catalytic process with use of Mn(II)/Co(II)/O2 system. Thus, a variety of carboxylic acids were prepared by the reaction of alkenes and dienes with acid anhydrides in the presence of a very small amount of Mn(OAc)2 (0.5 mol %) and Co(OAc)2 (0.1 mol %) under dilute dioxygen.
